AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BOSTON -- Estrogen-containing oral contraceptives appear to greatly increase the relative risk of venous thromboembolism among women with the factor V Leiden genetic mutation, according to a recent review by the World Health Organization.
Asked if they would prescribe estrogen-containing oral contraceptives for these women, members of a recent expert panel agreed they would not. The risks of a blood clot are too great, they said.
"I'd be very cautious about using estrogen. I would use methods that had progestin in them if the patient wanted a hormonal method at all," said panelist Sharon Schnare of the South Kitsap Family Care Clinic in Port Orchard, Wash.
"They really should not use a contraceptive method that has estrogen in it," agreed Dr. Michael Policar, medical director of the California state office of family planning.
The clinicians spoke during a conference on contraceptive technology sponsored by Contemporary Forums.
Clots: Relative and Absolute Risks
The evidence on the risks of VTE among women who carry factor V Leiden and who also take combined oral contraceptives (COCs) is murky. The research suffers from a variety of biases and sometimes offers conflicting assessments.
Source: HighBeam Research, Combo OC use in factor V Leiden not advised.(Gynecology)